10 Best Tools for Interpretation of Results in Biomedical Research

Why Interpreting Biomedical Lab Results Is Harder Than Analysing Them

Analysis turns raw measurements into numbers: a fold change, an IC₅₀, an adjusted p-value. Interpretation decides what those numbers mean biologically: which pathway moved, which regulator drove it, and whether the result agrees with published work.

A result that contradicts the literature is often a sample or protocol problem, not a discovery. STR profiling of 278 widely used tumour cell lines from 28 institutes found 46.0% cross-contaminated or misidentified (PMID: 28107433), and a survey of NCBI's Sequence Read Archive found mycoplasma contamination in 11% of 884 rodent and primate RNA-seq series (PMID: 25712092).

No single tool covers every result type. The tools below fall into five stages: statistics, gene set enrichment, networks and regulators, patient or pathway context, and literature checking. A sound workflow uses one or more from each stage that applies to your data.

The 10 Best Tools for Interpretation of Results in Life-Science Research

The tools are listed in the order you would use them, not ranked against one another. Each was chosen as an established option for its stage of interpretation. Seven have peer-reviewed methods papers; the citation counts in the table (Europe PMC, October 2026) show how widely those papers are used, not how accurate the tools are. This is not a head-to-head benchmark. BioSkepsis publishes this blog, and no independent evaluation of BioSkepsis has been published.

1. GraphPad Prism. Not an interpretation tool in the pathway sense, but misinterpretation often starts with the statistics. A screen of 186 articles found that 43% of enrichment analyses did not correct p-values for multiple testing (PMID: 35263338). Prism has no peer-reviewed methods paper; R is a free alternative.

2. GSEA. Tests whether a predefined gene set shifts coherently across a ranked list of all measured genes, without a significance cut-off; the original paper found shared pathways across two lung cancer survival studies where single-gene overlap was minimal (PMID: 16199517). Under permuted phenotypes, GSEA's permutation null kept p-value distributions approximately flat, whereas simple tests assuming gene independence produced an excess of low p-values (PMID: 23070592).

3. Enrichr. A browser-based over-representation tool that tests a gene list against many libraries at once, including pathways, transcription factor targets and disease signatures (PMID: 23586463; PMID: 27141961). For RNA-seq hit lists, standard over-representation tests are biased towards long genes unless gene length is modelled (PMID: 20132535).

4. Metascape. Combines functional enrichment, interactome analysis and gene annotation across more than 40 independent knowledgebases in one portal, and compares several gene lists side by side (PMID: 30944313). Useful for hits from several time points, cell lines or CRISPR screens.

5. STRING. Maps hits onto known and predicted protein–protein associations drawn from experiments, curated databases, co-expression and text mining, with a confidence score for each (PMID: 36370105). Network clusters can reveal a complex that a pathway list splits apart.

6. QIAGEN Ingenuity Pathway Analysis (IPA). Moves from "which pathways are enriched" to "which regulator could explain this pattern". Its Upstream Regulator, Mechanistic Network, Causal Network and Downstream Effects analyses score candidates against a causal network curated from the literature (PMID: 24336805).

7. Reactome. A manually curated knowledgebase that models biology as ordered molecular reactions (PMID: 37941124). Its analysis tool overlays expression data onto specific reaction steps, which is more precise than a pathway-level label.

8. cBioPortal. Places a cancer finding in patient context: alteration frequency across tumour cohorts, co-occurrence and mutual exclusivity, and survival where clinical data exist (PMID: 22588877; PMID: 23550210). Tumour purity confounds correlation and clustering of tumour expression data, so account for it before drawing conclusions (PMID: 26634437).

9. BioSkepsis. Built for results that have no gene list: a blot, a qPCR fold change, a dose-response curve. It retrieves relevant papers, reads them in full, and links every explanatory claim to a PMID. The contrast is with general-purpose LLMs, which fabricated 55% (GPT-3.5) and 18% (GPT-4) of their citations in one study (PMID: 37679503). No independent evaluation of BioSkepsis has been published. The walkthrough is in AI for interpreting lab results against the literature.

10. General-purpose LLMs. ChatGPT, Claude and Gemini perform unevenly on interpretation tasks. GPT-4 matched expert cell-type annotations fully or partially in over 75% of cell types in most of ten scRNA-seq datasets (PMID: 38528186). It proposed functions similar to the curated GO name for 73% of gene sets, but found common functions for only 45% of omics-derived gene clusters (PMID: 39609565). In rare-disease gene prioritisation it placed the diagnosed gene in its top 50 only 17.0% of the time, against 55.3% for Phen2Gene (PMID: 39255797). Claude can be connected to BioSkepsis; setup is in Claude Connection for Biomedical Research.

Pathway and Gene Set Enrichment Analysis: Common Pitfalls in Omics Interpretation

Enrichment is the most-used interpretation step in genomics and one of the most often misapplied. A screen of 186 open-access articles found that 95% of over-representation analyses did not use or report an appropriate background gene list, and 43% did not correct for multiple testing; re-analysis of seven RNA-seq datasets showed these errors changed results substantially (PMID: 35263338).

Method choice matters as much as settings. In a benchmark across 42 microarray and 15 RNA-seq datasets, self-contained methods frequently called all gene sets significant while competitive methods, including GSEA, frequently called none (PMID: 32026945). A comparison of 16 methods found that four had large false-positive rates under phenotype permutation (PMID: 24260172), and a survey of about 68 enrichment tools documented wide differences in statistics and gene set sources (PMID: 19033363).

Gene set libraries are a further source of error. Overlapping gene sets produce false positives whose significance comes only from overlap with another set (PMID: 28259142), and enrichment results from early and recent Gene Ontology versions showed low consistency, with 58% of annotations mapped to 16% of human genes (PMID: 29572502).

Interpreting Unexpected Western Blot, qPCR and Assay Results Against the PubMed Literature

Enrichment and network tools only apply when you have a gene list. Most bench results do not: a band at the wrong molecular weight, a qPCR fold change in the opposite direction, a dose-response curve that plateaus early. For these, interpretation means finding published work under comparable conditions and identifying what differs.

General-purpose LLMs propose explanations quickly, but their references are unreliable. ChatGPT-3.5 generated 115 references for medical content, of which 47% were fabricated, 46% were real but inaccurate, and 7% were authentic and accurate (PMID: 37337480). Across 636 citations in a second study, 55% from GPT-3.5 and 18% from GPT-4 were fabricated (PMID: 37679503). Grounding in databases helps but does not remove the problem: of 15,903 claims made by GeneAgent, an LLM agent that checks its output against 18 biological databases, 8% were refuted (PMID: 40721871).

Choosing a Results Interpretation Tool by Biomedical Research Role

A Suggested Workflow for Interpreting Biomedical Experimental Results

No published guideline sets out a single interpretation workflow. The order below follows the evidence on where errors enter; steps 1 to 3 are directly supported by the studies cited, while steps 4 and 5 rest on the tools' methods papers.

1. Controls and sample identity. Authenticate cell lines, since 46.0% of 278 tumour lines in one study were cross-contaminated or misidentified (PMID: 28107433); test for mycoplasma (PMID: 25712092); validate antibodies (PMID: 27595404); and follow MIQE for qPCR, including reference gene validation (PMID: 19246619).
2. Statistics. Choose the correct test and correct for multiple comparisons (PMID: 35263338). In single-cell data, test at the level of biological replicates: common single-cell methods found hundreds of differentially expressed genes with no real biological difference, while pseudobulk methods avoided this (PMID: 34584091).
3. Enrichment (omics only). GSEA on the full ranked list (PMID: 16199517), or Enrichr or Metascape on a hit list with an experiment-specific background (PMID: 26346307). Correct for gene-length bias in RNA-seq (PMID: 20132535) and report library versions (PMID: 29572502).
4. Networks and regulators. STRING for protein associations (PMID: 36370105); IPA for predicted upstream regulators (PMID: 24336805).
5. Patient or pathway context. cBioPortal for cancer genes (PMID: 23550210), with tumour purity in mind (PMID: 26634437); Reactome for reaction-level detail (PMID: 37941124).
6. Literature check. Compare your result with published studies under matching conditions, using a manual PubMed search or BioSkepsis, and verify every citation before it enters a manuscript (PMID: 37679503).

For a broader view of evidence tools, see 10 Best AI Tools for Life-Science Literature Review (2026).

Frequently Asked Questions About Interpreting Biomedical Lab and Omics Results